PHIO PHARMACEUTICALS CORP. — Key Metrics
13 years of history · ending 2024-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
EPS (Diluted)
$-9
Book Value Per Share
$6
Free Cash Flow Per Share
$-9
Cash Per Share
$7
Revenue Per Share
$0
OCF Per Share
$-9
Return on Equity↓-21.1pts
-114.8%
Return on Assets↓-20.7pts
-94.7%
Return on Invested Capital↓-20.6pts
-93.7%
Debt to Equity
0.00
Current Ratio↓-18.2% -$1
5.65
Quick Ratio↓-18.2% -$1
5.65
Asset Turnover
0.03
R&D / Revenue
1577.1%
SBC / Revenue
63.6%
Capex / Revenue
0.4%
Working Capital↓-63.6% -$8M
$5M
Net Current Asset Value↓-62.1% -$8M
$5M
Invested Capital↓-64.3% -$9M
$5M
OCF / Net Income↓-0.6% -$0
0.99
FCF / Net Income↓-0.8% -$0
0.99
Accruals Ratio (Sloan)↓-0.7pts
-0.7%
Net Debt↓-2429.9% -$6M
$-5M
Net Debt / EBITDA↑+2851.4% +$1
0.73
Interest Coverage↓-89.3% -$13K
1501.22
Cash Coverage↓-86.2% -$8K
1317.56
Capex Coverage↓-1435.2% -$7K
-7112.00
Tangible Common Equity↓-63.7% -$8M
$5M
TCE / Total Assets↓-0.4pts
82.3%
NOPAT↑+16.0% +$1M
$-6M
Cash ROIC↓-21.4pts
-114.2%
WC / Revenue
2043.7%
Capex / D&A↑+89.5% +$0
0.50
Reinvestment Rate↓-0.6pts
0.0%
Asset Growth vs Revenue Growth↓-3222.0pts
-3026.2%
Revenue 5Y CAGR
61.5%
Book Value 5Y CAGR↓-11.8pts
-3.9%
Stock Price (FY-end)↓-99.4% -$289
$2
Market Cap
$1M
P/S Ratio
6.14
P/B Ratio
0.30
P/TB Ratio
0.30
Enterprise Value
$-4M
EV / Sales
-17.16
FCF Yield
-501.8%
Shareholder Yield
-10.4%
R&D Yield
257.0%
Capex Yield
0.1%
Shares Variation (YoY)
240.1%
Beta (5Y)↑+16.2% +$0
0.70
Cost of Equity↑+0.5pts
8.0%
Cost of Debt (after tax)
-0.3%
52W High↓-99.3% -$1K
$10
52W Low↓-99.0% -$180
$2
Trailing Return 1Y↑+0.6pts
-73.7%
Trailing Return 5Y↑+0.1pts
-99.8%
F-Score (Piotroski)↑+0.0% +$0
2.00
Z-Score (Altman)
-38.09
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.